Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.94 USD | +3.16% | -9.54% | +26.72% |
20/03 | North American Morning Briefing : Markets on Hold -2- | DJ |
19/03 | JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5 | MT |
Business Summary
Number of employees: 123
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody Drug Conjugate
100.0
%
| 27 | 100.0 % | 37 | 100.0 % | +38.65% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 27 | 100.0 % | 37 | 100.0 % | +38.65% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Martin Huber
CEO | Chief Executive Officer | 64 | 13/20/13 |
Director of Finance/CFO | 46 | 10/19/10 | |
David Mott
CHM | Chairman | 58 | 31/12/31 |
Timothy Lowinger
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/08/01 |
Anna Protopapas
BRD | Director/Board Member | 59 | 02/15/02 |
Mohan Bala
PRN | Corporate Officer/Principal | - | 25/21/25 |
Chuck Miller
LAW | General Counsel | - | 31/20/31 |
Ashish Mandelia
AUD | Comptroller/Controller/Auditor | 50 | 01/19/01 |
Tushar Misra
PRN | Corporate Officer/Principal | 64 | 16/21/16 |
General Counsel | 50 | 26/21/26 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | 01/16/01 |
David Mott
CHM | Chairman | 58 | 31/12/31 |
Anna Protopapas
BRD | Director/Board Member | 59 | 02/15/02 |
Andrew Hack
BRD | Director/Board Member | 50 | 06/17/06 |
Martin Huber
CEO | Chief Executive Officer | 64 | 13/20/13 |
Lawrence Alleva
BRD | Director/Board Member | 74 | 05/17/05 |
Allene Diaz
BRD | Director/Board Member | 59 | 09/21/09 |
Willard Dere
BRD | Director/Board Member | 70 | 19/18/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 121,303,007 | 119,267,730 ( 98.32 %) | 0 | 98.32 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.72% | 360M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MRSN Stock
- Company Mersana Therapeutics, Inc.